Quench Bio scores $50 mln Series A

Cambridge, Massachusetts-based Quench Bio, a biotechnology company focused on severe inflammatory diseases, has raised $50 million in Series A funding.

27 January 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles